Am Heart J March 2018 PMID 29447772

The Optimal Anti-Coagulation for Enhanced-Risk Patients Post-Catheter Ablation for Atrial Fibrillation (OCEAN) trial.

Atul Verma, Andrew C T Ha, Paulus Kirchhof, Gerhard Hindricks, Jeff S Healey, Michael D Hill, Mukul Sharma, D George Wyse, Jean Champagne, Vidal Essebag, George Wells, Dhiraj Gupta, Hein Heidbuchel, Prashanthan Sanders, David H Birnie

Full text PDF Download social card

Mentions

Peak: 2 in Oct 2021

across 3 sources since Jan 2020

Extended reach

14,931

potential audience

Total likes

Video views

578

Mentions per month

Jan 2020 – Sep 2025

Where it's discussed

X / Twitter3 posts
YouTube2 videos
News2 articles

AI synopsis

What people are saying

Discussions show a balanced curiosity about the trial's implications, with references to specific patient factors like CHADSvasc scores and the importance of randomized controlled trials, using measured language such as 'especially the scope' and 'needed RCT,' which demonstrates thoughtful consideration of the research and its broader significance.

AgreementModerate agreement

Most discussions acknowledge the importance of the OCEAN trial and its focus on post-ablation anticoagulation therapy, with some highlighting the potential implications for clinical practice.

InterestModerate interest

Participants express moderate interest, noting the trial's relevance to ongoing debates about optimal long-term management after AF ablation.

EngagementModerate engagement

Comments reflect some depth, referencing details like CHADSvasc scores and the scope of discontinuation, suggesting active engagement with the research specifics.

ImpactModerate impact

The posts suggest the study may influence future research and treatment guidelines, indicating a moderate potential impact on clinical decision-making.

Abstract in brief

The OCEAN trial is a study designed to find out if rivaroxaban is better than aspirin (ASA) in preventing strokes and embolisms in patients who had successful atrial fibrillation (AF) ablation but are still at risk. The trial focuses on patients without recurrent AF for at least a year post-ablation and tracks various health outcomes over three years.
There is currently uncertainty about the best long-term blood-thinning treatment after AF ablation, with practice variations and limited evidence from randomized trials. The trial aims to provide clearer guidance on whether rivaroxaban or aspirin offers better protection against strokes in this patient group.
The study is prospective, multicenter, and randomized, involving about 1,572 patients divided into two groups, and will evaluate outcomes such as strokes, bleeding risks, cognitive function, quality of life, and healthcare costs to determine the optimal treatment strategy.

Read the full abstract

All mentions

Key Insights on Anticoagulation and Cardiology Challenges

Stopping oral anticoagulation after AF ablation is a core issue, alongside discussions on paradoxes such as the smokers paradox and chronic total occlusion PCI. Dr. John Mandrola reviews these topics in this week's…

Medscape · Mar 28, 2025 558 views

Cardiovascular Screening Outcomes and Beta-Blocker Insights

This week, John Mandrola MD discusses key findings from the Danish Cardiovascular Screening Trial. The trial, involving over 46,000 men aged 65-74, showed no significant reduction in mortality but indicated lower rates…

Medscape · Sep 5, 2025 20 views

Kamala Tamirisa MD

@KTamirisaMD · X

RT @SchakrabartiEP: @SDiederichsen @RenatoDLopes1 @HanCardiomd @DLBHATTMD @JAMA_current @KTamirisaMD @stopafib @DBelardoMD Especially the s…

Oct 11, 2021 · 1 share · 9,464 followers View post →

Shanta Chakrabarti

@SchakrabartiEP · X

Oct 11, 2021 · 4 likes · 1 share · 4,205 followers View post →

Yury Mareev

@YMareev · X

@drraviele off-OAC pts had lower CHADSvasc (2.3 vs 2.7) and LA size + some other differences. Need RCT in this field like ongoing OCEAN study https://t.co/rOI5mDfcxE

Jan 14, 2020 · 1 like · 681 followers View post →